Muscle Abnormalities in Children With XLH (MDmuscleXLH)

Prospective Analysis of Quantitative and Qualitative Muscle Abnormalities in Children With X-linked Hypophosphatemia (XLH)

XLH rickets is a rare disease with muscle weakness. Fat parameters such as IMAT and intraMAT could be increased in this disease. IMAT and intraMAT will be calculated on MRI for 11 XLH children versus 20 typically developing children. The investigator will compare the percentage of IMAT in the XLH group versus control group and the difference concerning the intraMAT between the two groups.

Study Overview

• Status: Not yet recruiting
• Conditions: Muscle Weakness; XLH
• Intervention / Treatment: Other: MRI

Detailed Description

Single-center, prospective, non-randomized, controlled study with XLH and healthy volunteer children.

This study involves performing muscle MRI in healthy child volunteers to assess and compare the structure and composition of muscles to those of muscles in children with XLH pathology (muscle MRI of XLH patients is performed as part of standard medical care).

During this study we will have two groups: XLH group and a control group with typically developing children. In the XLH group, composed of 10 patients aged between 5 ans 17 years, female or male and ongoing growth (lesser bone age than 15 years old), have XLH and the most severe radiological deformities,clinical complications (pain and muscular weakness), have already done a muscle MRI of the lower limb during their follow-up.

The control group composed of 20 healthy volunteers aged between 5 ans 17 years old, female or male and without any endocrine pathology. A muscle MRI is necessary for healthy volunteers.

Every child will be alone After signing the informed consent by the 2 parents, the patient or the healthy volunteer and his parents, the MRI assessment will be performed on the same day.

Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, i.e. approximately 45 minutes.

Performing MRI does not require the injection of contrast products or radiopharmaceuticals.

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Agnés LINGLART, Pr; Phone Number: 0145217116; Email: agnes.linglart@aphp.fr
• Study Contact Backup: Name: Philippe WICART, Pr; Phone Number: 0144494310; Email: p.wicart@aphp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 5 years to 17 years (Child)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria common criteria to the 2 groups:

• Age: between 5 and 17 years.
• Sex: male or female.
• Informed consent, signed by both parents or holder of parental autority after being informated of the study.
• Affiliation to a social security schema or having the right to.

Inclusion criteria for XLH Patients :

• Patient suffer of X-linked hypophosphatemia rickets.
• Severity of clinical and radiological damage (pain, muscle weakness and severe bone deformities).
• Growth in progress (bone age less than 15 years).
• Child under conventional treatment: patient responding to conventional treatment or
• under treatment with Burosumab (patient in treatment failure under treatment conventional).

incluion criteria for helthy volunteers :

• Healthy voluntary subjects, not suffering from XLH.
• Matching by age (+/- 6 months) and sex.

Exclusion Criteria common to the 2 groups :

• Not being able to stay still during the MRI examination (approximately 45 min).
• Growth completed.
• History of lower limb surgery.
• Contraindications to MRI
• Holders of parental authority under AME.
• Holders of parental authority under tutorship / curatorship.

Exclusion criteria for Healthy volunteers :

• Patients with endocrine, contracted or muscular pathology.
• Patient receives a long-term treatment.
• Patients with a high athletic level.
• BMI-IOTF <20 or> 27.8

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: patients with X-linked hypophosphatemic; Patient group composed of 10 patients aged between 5 to 17 years old, female or male, with X-linked hypophosphatemic (XLH) rickets, severity of clinical and radiological damage (pain, muscle weakness and severe bone deformities) and ongoing growth (lesser bone age than 15 years old), child under conventional treatment	Other: MRI; Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes. Performing MRI does not require the injection of contrast products or radiopharmaceuticals.
Other: healthy volunteers; control group composed of 20 helthy volunteers aged between 5 to 17 years old, female or male, without any endocrine pathology, not suffering from XLH, matching by age (+/- 6 months) and sex	Other: MRI; Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes. Performing MRI does not require the injection of contrast products or radiopharmaceuticals.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quantify and compare muscle composition in XLH children versus healthy control children to demonstrate a link between muscle function and muscle quality.	calculation of inter-muscular adipose tissue will be done in cm2	1 day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of muscle strength on force platforms, during gait analysis. Power test by mechanography of the jump (bipod and monopodal). Grasping test and correlation of fatty infiltration and functional data.	The Outcome Measure is BMI (Kg/m²)	1 day
Quantitative analysis of the muscles of the lower limbs (volume and length)	The Outcome Measure is BMI (Kg/m²)	1 day

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Anticipated): April 15, 2022
• Primary Completion (Anticipated): June 15, 2023
• Study Completion (Anticipated): June 15, 2023

Study Registration Dates

• First Submitted: January 24, 2022
• First Submitted That Met QC Criteria: March 28, 2022
• First Posted (Actual): April 5, 2022

Study Record Updates

• Last Update Posted (Actual): April 5, 2022
• Last Update Submitted That Met QC Criteria: March 28, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: MRI; muscle weakness; XLH rickets; IMAT; intraMAT
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Neurologic Manifestations; Musculoskeletal Diseases; Muscular Diseases; Neuromuscular Manifestations; Muscle Weakness; Paresis
• Other Study ID Numbers: 2020-A01386-33

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No